Two drug-eluting stents from Boston Scientific have become the first to be approved by the FDA for treating patients with acute myocardial infarction (AMI), the company announced.
The paclitaxel-eluting Ion and Taxus Liberté stents gained approval for AMI primarily on the strength of the evidence from the HORIZONS-AMI trial.
HORIZONS-AMI randomized 3,006 patients to bare-metal or Taxus stents. At three years, there were no significant differences in safety, including all-cause death, reinfarction, stent thrombosis, or stroke.
Read the full story: http://hcp.lv/yWMJQg
Source: MedPage Today